BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/15/2026 6:19:37 AM | Browse: 9 | Download: 4
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 120863
DOI 10.4251/wjgo.120863
Country Spain
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Albumin-bilirubin score is a prognostic factor in hepatocellular carcinoma treated with transarterial radioembolization: A retrospective cohort study
Manuscript Source Unsolicited Manuscript
All Author List Álvaro Suárez-Toribio, Ignacio López-Bueno, Javier Ampuero-Herrojo, Manuel Cabanillas-Casafranca, Álvaro Giráldez-Gallego, José Manuel Sousa-Martín, Juan Luis Tirado-Hospital, Álvaro Iglesias-López, Verónica Nacarino-Mejías and María Teresa Ferrer-Ríos
Funding Agency and Grant Number
Corresponding Author Álvaro Suárez-Toribio, Researcher, Department of Gastroenterology, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot, Sevilla 41013, Andalusia, Spain. alvarostoribio@gmail.com
Key Words Hepatocellular carcinoma; Selective internal radiation therapy; Albumin-bilirubin score; Yttrium-90; Satellite nodules
Core Tip Selective internal radiation therapy is an established treatment for hepatocellular carcinoma, but prognostic stratification remains challenging. In this real-world cohort, the albumin-bilirubin score emerged as a key factor associated with overall survival, compared with conventional clinical parameters. These findings confirm that albumin-bilirubin is a simple, objective tool for patient selection and risk stratification, which can improve treatment decisions for patients undergoing selective internal radiation therapy.
Citation Suárez-Toribio Á, López-Bueno I, Ampuero-Herrojo J, Cabanillas-Casafranca M, Giraldez-Gallego A, Sousa-Martín JM, Tirado-Hospital JL, Iglesias-López Á, Nacarino-Mejías V, Ferrer Ríos MT. Albumin-bilirubin score is a prognostic factor in hepatocellular carcinoma treated with transarterial radioembolization: A retrospective cohort study. World J Gastrointest Oncol 2026; In press
PDF 120863-in-press.pdf
Received
2026-03-10 00:32
Peer-Review Started
2026-03-10 00:33
First Decision by Editorial Office Director
2026-04-17 08:08
Return for Revision
2026-04-18 08:04
Revised
2026-05-17 15:37
Publication Fee Transferred
2026-05-21 16:48
Second Decision by Editor
2026-06-15 02:39
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-06-15 06:19
Articles in Press
2026-06-15 06:19
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com